Sun Pharma launches Volini Maxx with Virat Kohli

Sun Pharma launches Volini Maxx with Virat Kohli

Volini Maxx is a new variant of Sun Pharma’s popular brand, Volini.

Sun Pharma

MUMBAI: Sun Pharma Consumer Healthcare, a division of Sun Pharmaceutical Industries has launched Volini Max.

The company has signed Virat Kohli, captain of Indian cricket team as the new brand ambassador of Volini. A 360 degree marketing campaign featuring Virat Kohli goes live today. 

Kohli says, “I’m happy to partner with Volini and announce the launch of Volini Maxx - India’s strongest pain relief spray. Athletes are required to push through pain on a regular basis, and Volini has been my trusted pain relief partner for decades. With its instant pain relief formulation, I am able to focus on my game and not the pain.” 


Volini Maxx is a new variant of Sun Pharma’s popular brand, Volini. Its unique formulation of 2 per cent diclofenac makes it 100 per cent stronger than the existing 1 per cent diclofenac sprays available in the Indian market. Volini Maxx is targeted for severe pains including musculoskeletal, joint and low back.

Sun Pharma CEO India for emerging markets and consumer healthcare Kal Sundaram mentions, “Volini has been a trusted pain relief partner for over two decades. We are happy to introduce Volini Maxx spray which is stronger than any other topical pain relief spray available in India*. It will provide effective relief to people suffering from back and joint pain & also in sports injuries. Known for pushing the limits of physical endurance, Virat echoes the brand vision of constantly improving performance and not letting pain come in the way of going that extra mile.”

Lowe Lintas President Madhu Noorani adds, "Virat Kohli headlines more than every cricket match he plays. He is celebrated for his consistent performance and unmatched levels of fitness. Unstoppable, he is always seen firing on all cylinders on the field. However, this does not come easy in today’s demanding competitive cricket world. A sportspersons life, more than anyone else’s, is liberally sprinkled with injuries and when you are knocked down, what matters most is how quickly you can come back to the game.”

The overall topical analgesic market in India is valued at Rs 3380 crore growing at 11 per cent. Out of this, the spray category is around Rs 356 crore growing at 18 per cent, according to Nielsen MAT June 2018 report.

Sun Pharma is the world's fifth largest specialty generic pharmaceutical company and India's top pharmaceutical company.

Sun Pharma's global presence is supported by 42 manufacturing facilities spread across six continents, R&D centres across the globe and a multi-cultural workforce comprising over 50 nationalities. In India, the company enjoys leadership across 13 different classes of doctors with 32 brands featuring amongst top 300 pharmaceutical brands in India. Its footprint across emerging markets covers over 100 markets and six markets in Western Europe.